ADPT

Adaptive Biotechnologies Corporation Common Stock (ADPT) | Rumor.io

Adaptive Biotechnologies

ADPT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,180

Bullish sentiment (50-day avg)98%

Price to earnings ratio-73.1

Market capitalization4.6B

Earnings per share-0.4

Dividend yield (TTM)—

Revenue (annual)277M

Net income (annual)-59.5M

Social

What share of all stock conversation is about ADPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 9

BTIG is bullish on ADPT, setting a $22 target, indicating potential upside for the stock.
A strong breakout above the 200 MA on heavy volume suggests a potentially bullish trend, but a pullback is expected before a preferred entry point.
Morgan Stanley maintains an equal-weight rating for ADPT, and the company's recent convertible senior notes issuance has a conversion price of $24.11, but with capped calls purchased up to $34.44, there should be minimal dilution unless the stock price surpasses $34.44.

Generated by AI

Sentiment

Of the messages about ADPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	99.04% +19.04	98.17% +3.43	97.69% +6.9
Bearish	—	0.96% -19.04	1.83% -3.43	2.31% -6.9

Bullish· Jul 2

$ADPT has a strong entry point for long-term gains, with the potential to reach $25.
The company's partnerships with Microsoft and Roche are significant, making ADPT a promising investment opportunity.
ADPT's low float and high volume in recent days suggest a potential price increase, making it a good time to buy and hold.

Bearish· Jul 1

$ADPT's recent performance may be a sign of weakness following a pullback in another recent healthcare IPO.
The low float of $ADPT makes it vulnerable to manipulation, leading to potential price volatility.
$ADPT's price is likely to continue falling due to a lack of demand and the presence of short-term traders.

Generated by AI

Topics

Of the messages about ADPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0%	52%	90.16%	16.88%
Announcements	45.45%	20%	4.1%	25.45%
Analysts	54.55%	28%	5.74%	20.24%
Controversies	0%	0%	0%	0.13%
Earnings	0%	0%	0%	18.74%
Macro	0%	0%	0%	18.56%

Earnings· Feb 22

The earnings expectation for Adaptive Biotechnologies Corporation ($ADPT) is questioned, with skepticism around the potential for EPS of $0.22.
The company's Management Services revenue is seen as a key factor in achieving the expected EPS of $0.22.
There is still no official announcement from Adaptive Biotechnologies Corporation regarding the earnings date.

Announcements· Mar 8

Adaptive Biotechnologies (ADPT) received emergency use authorization from the FDA for its "T-Detect" test to confirm recent or prior Covid-19 infection.
The company's shares soared 11.3% in premarket action following the announcement.
The FDA's emergency use authorization allows the T-Detect test to be used to confirm recent or prior Covid-19 infection in patients.

Technical Analysis· Apr 13

$ADPT is trading in a range between $2.35 and $2.50, with a potential breakout above $2.50.
The stock is showing a Cup and Handle chart pattern, with support holding strong around $2.42-$2.45.
A double bottom formation is possible, with the stock waiting for a bounce back up after a weak close and a red-to-green move.

Generated by AI

Community

Of the messages about ADPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	40%	11.88%	48.23%	34.3%
Newcomers	60%	88.13%	51.77%	65.7%

Regulars· Feb 15

Adaptive Biotechnologies Corporation's Q4 loss and lagging revenue estimates have raised concerns, with the company's stock price increasing by 6.6% pre-market.
Credit Suisse has maintained its Underperform rating and $7 price target for Adaptive Biotechnologies Corporation, citing the company's disappointing Q4 results.
Despite some positive momentum, Adaptive Biotechnologies Corporation's stock price remains under pressure, with some analysts and traders expressing skepticism about the company's future prospects.

Newcomers· Dec 21

Piper Sandler has upgraded Adaptive Biotechnologies (ADPT) to Overweight, with a new price target of $14, indicating a potential 87% upside.
The upgrade has resulted in a significant price increase, with ADPT shares trading at $7.74, a 9.17% gain.
Analyst D. Westenberg has a high accuracy rate of 71% and has raised the price target from $7.5 to $14, citing the company's biotechnology sector and low short float of 3.78%.

Generated by AI

Adaptive Biotechnologies has seen its share price move sharply in recent years, and the question now is whether the cash flows the business can generate really back up that kind of ride. With the stock recently closing at US$29.57 and investor attention drawn to new clinical guideline support for its testing platform, the focus turns to what the current valuation says about its future cash streams. Over the past 3 years the stock has returned about 432.8%, which puts a lot of weight on the...

4d agoYahoo Finance

Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?

Adaptive Biotechnologies (ADPT) is back in focus after the National Comprehensive Cancer Network updated multiple myeloma guidelines to more fully embed minimal residual disease testing and explicitly reference the company’s clonoSEQ assay. Investors have reacted quickly to the guideline update, with Adaptive Biotechnologies’ share price up 6.02% over the past day and posting a 12.65% 30-day share price return, while the 1-year total shareholder return of 125.21% and 3-year total shareholder...

5d agoYahoo Finance

Adaptive Biotechnologies stock hits 52-week high at 28.79 USD

5d agoInvesting.com

NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies recently highlighted updates to the National Comprehensive Cancer Network multiple myeloma guidelines, which now feature a dedicated page on minimal residual disease testing and specifically reference its FDA-cleared clonoSEQ assay with preferred high-sensitivity thresholds and expanded testing timepoints. The inclusion of clonoSEQ by name, alongside broader recommendations for routine and longitudinal MRD assessment, strengthens its position as a standardized tool...

6d agoYahoo Finance

Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) highlighted updated National Comprehensive Cancer Network, or NCCN, multiple myeloma guidelines on September 17. According to the announcement, the recommendations specifically name clonoSEQ and expand testing time points to include annual assessments during maintenance and testing after later treatment lines. The update strengthens the case for monitoring minimal residual disease, or […]

7d agoYahoo Finance

Also Discussed

Investors talking about ADPT also mention

#	Name	Attention
1	Community Health Systems IncCYH	0%new
2	Statera Biopharma Inc.STAB	0%0
3	Banc of California, Inc.BANC	0%new
4	Tidewater Inc.TDW	0%0
5	China Auto Logistics Inc.CALI	0.06%-0.49
6	Gyre Therapeutics Inc.GYRE	0%0
7	Vince Holding Corp.VNCE	0%0
8	Acadia Healthcare Company, Inc.ACHC	0%new
9	ALPN - Alpine Immune Sciences, Inc.	——
10	ATXS - Astria Therapeutics, Inc.	——

Adaptive Biotechnologies Corporation Common Stock

Healthcare
Diagnostics & Research

Adaptive Biotechnologies Corporation Common Stock represents the equity of Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company focused on immune medicine. The company develops products and services that use immunosequencing, proprietary chemistry, computational biology, and machine learning to analyze the adaptive immune system and support clinical diagnostics, life sciences research, and drug discovery. Its portfolio includes clonoSEQ, a test used to detect and monitor minimal residual disease in cancer patients, along with immunoSEQ-based offerings for immune profiling and research applications. Adaptive Biotechnologies serves healthcare providers, pharmaceutical partners, researchers, and biotech collaborators across oncology and broader immunology-related markets. Headquartered in Seattle, Washington, the company plays a specialized role in translating immune system data into tools for disease detection and treatment support.

Website

Location

1165 Eastlake Avenue East

Seattle, WA, 98109

United States

Social

What share of all stock conversation is about ADPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 9

BTIG is bullish on ADPT, setting a $22 target, indicating potential upside for the stock.
A strong breakout above the 200 MA on heavy volume suggests a potentially bullish trend, but a pullback is expected before a preferred entry point.
Morgan Stanley maintains an equal-weight rating for ADPT, and the company's recent convertible senior notes issuance has a conversion price of $24.11, but with capped calls purchased up to $34.44, there should be minimal dilution unless the stock price surpasses $34.44.

Generated by AI

Sentiment

Of the messages about ADPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	99.04% +19.04	98.17% +3.43	97.69% +6.9
Bearish	—	0.96% -19.04	1.83% -3.43	2.31% -6.9

Bullish· Jul 2

$ADPT has a strong entry point for long-term gains, with the potential to reach $25.
The company's partnerships with Microsoft and Roche are significant, making ADPT a promising investment opportunity.
ADPT's low float and high volume in recent days suggest a potential price increase, making it a good time to buy and hold.

Bearish· Jul 1

$ADPT's recent performance may be a sign of weakness following a pullback in another recent healthcare IPO.
The low float of $ADPT makes it vulnerable to manipulation, leading to potential price volatility.
$ADPT's price is likely to continue falling due to a lack of demand and the presence of short-term traders.

Generated by AI

Topics

Of the messages about ADPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0%	52%	90.16%	16.88%
Announcements	45.45%	20%	4.1%	25.45%
Analysts	54.55%	28%	5.74%	20.24%
Controversies	0%	0%	0%	0.13%
Earnings	0%	0%	0%	18.74%
Macro	0%	0%	0%	18.56%

Earnings· Feb 22

The earnings expectation for Adaptive Biotechnologies Corporation ($ADPT) is questioned, with skepticism around the potential for EPS of $0.22.
The company's Management Services revenue is seen as a key factor in achieving the expected EPS of $0.22.
There is still no official announcement from Adaptive Biotechnologies Corporation regarding the earnings date.

Announcements· Mar 8

Adaptive Biotechnologies (ADPT) received emergency use authorization from the FDA for its "T-Detect" test to confirm recent or prior Covid-19 infection.
The company's shares soared 11.3% in premarket action following the announcement.
The FDA's emergency use authorization allows the T-Detect test to be used to confirm recent or prior Covid-19 infection in patients.

Technical Analysis· Apr 13

$ADPT is trading in a range between $2.35 and $2.50, with a potential breakout above $2.50.
The stock is showing a Cup and Handle chart pattern, with support holding strong around $2.42-$2.45.
A double bottom formation is possible, with the stock waiting for a bounce back up after a weak close and a red-to-green move.

Generated by AI

Community

Of the messages about ADPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	40%	11.88%	48.23%	34.3%
Newcomers	60%	88.13%	51.77%	65.7%

Regulars· Feb 15

Adaptive Biotechnologies Corporation's Q4 loss and lagging revenue estimates have raised concerns, with the company's stock price increasing by 6.6% pre-market.
Credit Suisse has maintained its Underperform rating and $7 price target for Adaptive Biotechnologies Corporation, citing the company's disappointing Q4 results.
Despite some positive momentum, Adaptive Biotechnologies Corporation's stock price remains under pressure, with some analysts and traders expressing skepticism about the company's future prospects.

Newcomers· Dec 21

Piper Sandler has upgraded Adaptive Biotechnologies (ADPT) to Overweight, with a new price target of $14, indicating a potential 87% upside.
The upgrade has resulted in a significant price increase, with ADPT shares trading at $7.74, a 9.17% gain.
Analyst D. Westenberg has a high accuracy rate of 71% and has raised the price target from $7.5 to $14, citing the company's biotechnology sector and low short float of 3.78%.

Generated by AI

Adaptive Biotechnologies

Social

Jul 9

Bullish· Jul 2

Bearish· Jul 1

Earnings· Feb 22

Announcements· Mar 8

Technical Analysis· Apr 13

Regulars· Feb 15

Newcomers· Dec 21

Adaptive Biotechnologies CPO Francis Lo sells $3.2 million in stock

Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update

Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?

Adaptive Biotechnologies stock hits 52-week high at 28.79 USD

NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?

Also Discussed

Adaptive Biotechnologies Corporation Common Stock

Company Information

Location

Adaptive Biotechnologies CPO Francis Lo sells $3.2 million in stock

Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update

Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?

Adaptive Biotechnologies stock hits 52-week high at 28.79 USD

NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?

Also Discussed

Social

Jul 9

Bullish· Jul 2

Bearish· Jul 1

Earnings· Feb 22

Announcements· Mar 8

Technical Analysis· Apr 13

Regulars· Feb 15

Newcomers· Dec 21